



# Cell Differentiation Agents Recommended for the Rescue of Metastatic, Unresponsive and Recurrent Cancer Patients

Ming C. Liao <sup>a\*</sup>, Christine L. Craig <sup>a</sup> and Linda L. Baker <sup>a</sup>

<sup>a</sup> CDA Therapeutics, Inc., 3088 Sky Run Court, Missouri City, TX 77459, USA.

## **Authors' contributions**

*This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.*

## **Article Information**

DOI: <https://doi.org/10.9734/jcti/2024/v14i2254>

## **Open Peer Review History:**

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/117442>

**Commentary**

**Received: 19/03/2024**

**Accepted: 23/05/2024**

**Published: 07/06/2024**

## **ABSTRACT**

The objective of this article is to develop cell differentiation agent (CDA) formulations to the rescue of cancer patients whose cancer stem cells (CSCs) have become a dominant issue such as metastatic, unresponsive and recurrent cancer patients. Although CSCs are only a small minor subpopulation, they contribute the major fatal effects of cancer, such as metastasis, unresponsiveness, recurrence, drug resistance and angiogenesis. These cells are protected by drug resistance and anti-apoptosis mechanisms, and, therefore, are very resistant to therapies aimed to kill cancer cells (CCs). Perfect cancer drugs must be able to take out both CCs and CSCs, to restore chemo-surveillance. Imperfect cancer drugs can only solve a fraction of cancer problems. Cytotoxic chemotherapeutic drugs, radiation, apoptosis inducing drugs and immunotherapeutic drugs put up by cancer establishments are imperfect cancer drugs which can only kill CCs but cannot affect CSCs. These imperfect cancer drugs also cause damage to chemo-

\*Corresponding author: Email: [mingliao@yahoo.com](mailto:mingliao@yahoo.com);

**Cite as:** C. Liao, Ming, Christine L. Craig, and Linda L. Baker. 2024. "Cell Differentiation Agents Recommended for the Rescue of Metastatic, Unresponsive and Recurrent Cancer Patients". *Journal of Cancer and Tumor International* 14 (2):28-37. <https://doi.org/10.9734/jcti/2024/v14i2254>.

surveillance. The inability to eliminate CSCs and the damage to chemo-surveillance are responsible for the failure of imperfect cancer drugs to save advanced cancer patients that include metastatic, unresponsive and recurrent cancer patients.

CDA formulations are perfect cancer drugs made up by differentiation inducers (DIs) and differentiation helper inducers (DHIs), which can induce both CSCs and CCs to undergo terminal differentiation. Evidently, induction of terminal differentiation is the only option for the solution of CSCs. And the solution of CSCs is essential to cure cancer. DIs and DHIs are the active players of chemo-surveillance to restore the functionality of chemo-surveillance often badly damaged in cancer patients. Thus, CDA formulations are the right solution to the rescue of cancer patients with CSCs as a dominant issue.

*Keywords: Cancer cells; cancer stem cells; chemo-surveillance; differentiation inducers; differentiation helper inducers; methylation enzymes; wound healing.*

## 1. INTRODUCTION

“Cancer is an old and unsolved problem. Evidently, cancer therapies based on killing of CCs are ineffective to save advanced cancer patients. That is why cancer mortality continues to increase. Recent cancer diagnoses of royal family members offer a supreme authority to rectify cancer therapy to save cancer patients” [1]. “Immuno-surveillance and chemo-surveillance are the nature’s creation of protection mechanisms to ward off cancer, immune-surveillance by eliminating the damages created by infectious agents, and chemo-surveillance by eliminating the damages created by toxic chemicals, including carcinogens. Cancer arises if such protection mechanisms fail to function. Cancer therapies based on killing of CCs can only benefit early stage cancer patients, whose chemo-surveillance have not yet fatally damaged, relying on the recovery of chemo-surveillance to subdue surviving CSCs” [2]. “Advanced cancer patients require cell differentiation agent (CDA) formulations to restore the functionality of chemo-surveillance to achieve cancer therapy” [3]. “The success of cancer therapy depends on the success of the elimination of CSCs. CDA formulations are very effective on CSCs” [4]. “Metastasis is the making of CSCs. Therefore, CSCs are a dominant issue of metastatic cancer patients. CSCs are also a dominant issue of unresponsive and recurrent cancer patients. Elimination of CSCs is very critical to the success of cancer therapy” [5-7]. Somehow, cancer establishments are trapped in belief that killing of CCs is the most important matter and ignore CSCs. That strategy does not seem to work as cancer mortality keeps on increasing.

“Cancer evolves as a consequence of wound unhealing” [8-10]. “The nature creates chemo-surveillance to ensure perfection of wound

healing” [11]. “Wound healing requires the proliferation and the terminal differentiation of progenitor stem cells (PSCs)” [12]. Wound unhealing is due to the collapse of chemo-surveillance [13,14], but the nature does not have a mechanism to detect the collapse of chemo-surveillance to make correction. “So, the nature responds by forcing progenitor stem cells (PSCs) to proliferate. The build up of PSCs is limited by contact inhibition. PSCs are then forced to evolve into CSCs to escape contact inhibition. By a single hit to silence ten-eleven translocator-1 (TET-1) enzyme, the enzyme responsible for lineage transitions, PSCs can be converted to CSCs, which is within the reach of PSCs since these cells are equipped with abnormally active methylation enzymes, which play a pivotal role on the regulation of cell replication and differentiation. The evolved CSCs are still unable to undergo terminal differentiation to heal the wound because the collapsed chemo-surveillance remains unsolved. CSCs are then forced to progress to faster growing CCs by chromosomal translocations to activate oncogenes or deletions to inactivate suppressor genes. Thus, carcinogenesis is a process of wound unhealing that forces PSCs to evolve into CSCs, and then to progress to faster growing CCs. Reversal of this process is the right approach of cancer therapy” [15,16]. “Evidently, CDA formulations made up by differentiation inducers (DIs) and differentiation helper inducers (DHIs) involved in wound healing are the best drugs to take out CSCs as a dominant issue. DIs and DHIs are wound healing metabolites effective to destabilize abnormal MEs of PSCs to achieve terminal differentiation. DIs are chemicals capable of eliminating telomerase of abnormal MEs, and DHIs are inhibitors of MEs capable of potentiating the activity of DIs. Abnormal MEs pass on from PSCs to CSCs, and then from

CSCs to CCs. Cells with abnormal MEs gain great advantage on cell growth. Cancer is basically a problem of growth regulation going awry. MEs play a pivotal role on the regulation of cell growth, and, therefore, are critically related to cancer. Destabilization of abnormal MEs provides the best approach for cancer therapy” [2-7]

## 2. COMMENTARIES AND DISCUSSION

### 2.1 CSCs as A Very Critical Issue of Cancer

“Although CSCs constitute only a small minor subpopulation, these cells contribute the major fatal effects of cancer, fatal effects such as metastasis, unresponsiveness, recurrence, drug resistance and angiogenesis. The solution of CSCs is very critical to the success of cancer therapy” [5-7]. “But cancer establishments ignore the important issue of CSCs [17,18]. They tend to pay attention to the very visible but not so critical issue of cancer. CCs make up the absolute majority of tumor mass. They put up imperfect cancer drugs to eliminate CCs, such as cytotoxic chemotherapeutic agents, radiation, apoptosis inducing drugs and immunotherapeutic drugs which cannot affect CSCs” [19-23]. “Imperfect cancer drugs can only benefit a small % of cancer patients in the early stage whose chemo-surveillance have not yet been fatally damaged, allowing the recovery of chemo-surveillance to subdue surviving CSCs, whereas these drugs cause fatality of majority of cancer patients in advanced stage whose chemo-surveillance have been fatally damaged” [11,13,14]. “The inability to eliminate CSCs and the contribution to the damage of chemo-surveillance are responsible for the failure of imperfect cancer drugs to put cancer away. Cancer mortality remains at historical high, and keeps on increasing. According to NCI experts, cancer incidence and mortality worldwide in 2019 were 19 million and 10 million, respectively, which were exactly 5% above the statistics of 2018” [24]. “They predicted an annual increment of 5% likewise in the following years. President Joe Biden brought up cancer moonshot initiative in 2022, requesting a reduction of cancer mortality by 50% in 25 years” [25]. A drastic change of cancer leaderships away from those focused on killing of CCs is necessary to fulfill the goal of cancer moonshot initiative [1,26]. Development of drugs effective against CSCs is very critical to save cancer patients to reduce cancer mortality, since CSCs are responsible for

the most fatal effects of cancer [5-7]. CDA formulations are the drugs very effective to eliminate CSCs. The development of CDA formulations is, therefore, very important for the success of cancer therapy. But the development of CDA formulations has been blocked by cancer establishments, since these agents cannot cause the disappearance of tumor they set up as a criterion to evaluate the effectiveness of cancer therapy. That is a grave mistake committed by the cancer establishments to result in the failure of cancer therapy. Health profession is an authoritarian profession. When the mistake is made by the very top of the profession, there is no mechanism to rectify the mistake. The mistake carries on to hurt cancer patients. This is the reason of the horrendous cancer mortality of more than 10 million annually worldwide. Cancer establishments in the USA are also not successful to reduce cancer mortality. But they are doing better than the world data shown. The increment of cancer mortality is only 0.2% in 2023 [24], which is still far from the request of reducing annual mortality of 2% by President Biden. Obviously, the commanding principle of killing CCs is unable to reduce cancer mortality.

### 2.2 Wound Healing as A Very Important Health Issue

“Wound healing is a very important health issue, so that the nature creates chemo-surveillance to ensure perfection of wound healing to avoid disastrous consequences of wound unhealing, that can be tissue fibrosis, dementia, organ failure and cancer” [8-11,19,27]. “Chemo-surveillance was a term we created to describe the nature’s creation of protection mechanism to benefit humans” [11]. Chemo-surveillance was based on the quantitative analyses of plasma and urinary peptides. Peptides share physical chemical properties of wound healing metabolites DIs and DHIs, therefore can be used as surrogate molecules to represent DIs and DHIs. Acidic peptides are actually very active DIs [7,28]. Quantitative analyses of plasma and urinary peptides through initial purification by C18 cartridge, followed by HPLC resolution of peptides on a column of sulfonated polystyrene and Ninhydrin reaction allowed us to show that healthy people were able to maintain a steady level of CDA at level 5, whereas only 2% of cancer patients could maintain this high level, 25% at CDA level above 3, and 75% at CDA level below 3. CDA levels reflect very well the severity of cancer patients. It appears that the damage to chemo-surveillance allows cancer to

occur, the progression of cancer causes CDA levels to decline further, and the treatment with cytotoxic agents accelerate the decline of CDA levels. Antineoplastons are preparations of urinary DIs and DHIs by reverse phase chromatography on C18 [29]. If patients responded well to Antineoplaston therapy, CDA levels would increase to approach CDA level at the healthy level of 5. If not, CDA levels continued to decline [30]. This is a clear indication that the collapse of chemo-surveillance is responsible for cancer to occur, and the restoration of chemo-surveillance can lead to the cure of cancer. Evidently, not all patients responded positively to Antineoplaston therapy. Antineoplastons are preparations of natural wound healing metabolites. Cancer cells, particularly those replicating very fast, are known to express a high level of degradative enzymes to salvage substrates for the syntheses of macromolecules to support faster growth. Natural metabolites may be quickly degraded to lose activities. For cancer therapy, it is advisable to provide two sets of CDA formulations: one set CDA-CSC with natural DIs and DHIs which can easily access CSCs but may not resist destruction of degradative enzymes of CCs, and another set CDA-CC with non-natural DIs and DHIs which may not access CSCs but can resist destruction of degradative enzymes of CCs. Natural DIs are arachidonic acid (AA) and its metabolites prostaglandin derivatives (PGs) [31,32], and natural DHIs are inhibitors of MEs such as steroid metabolites, uroerythrin, fatty acid and amino acid derivatives [33-37]. Unnatural DIs and DHIs are synthetic chemicals functioning as inhibitors of telomerase or MEs [31,36].

“Wound healing and cancer are closely related to involve progenitor stem cells (PSCs) as the common elements” [12,38,39]. Wound triggers biological and immunological responses. The biological response involves the release of arachidonic acid AA from membrane bound phosphatidylinositol for the synthesis of prostaglandins PGs [40], which are good for wound healing. PGs are excellent DIs [31,32] and very active inflammatory agents (41). “PGs are metabolically unstable with very short half lives. They are produced at the initial phase of wound. Their effect on wound healing is believed to trigger inflammatory response to result in edema for the extravasation of inhibitors such as DIs and DHIs in order for PSCs to proliferate. The promotion of terminal differentiation of PSCs at the final phase of wound is carried out by

chemo-surveillance. Thus, the functionality of chemo-surveillance dictates the success of wound healing” [13,14]. “The stable end products of PGs are also active as DIs, although not as good as PGs” [32]. “These stable end products of PGs may play a significant role as DIs on wound healing. The immunological response of wound prompts the production of cytokines which are bad for wound healing [41]. Tumor necrosis factor (TNF) among cytokines produced is particularly bad on wound healing. TNF is also named cachectin after its effect to cause cachexia symptoms. A manifestation of cachexia symptoms is excessive excretion of low molecular weight metabolites due to the membrane hyperpermeability caused by TNF” [42,43]. DIs and DHIs are among low molecular weight metabolites excreted, resulting in the collapse of chemo-surveillance to cause wound unhealing and the disastrous consequences of wound unhealing.

In the case of acute wound, biological response prevails to favor wound healing. In the case of chronic wound, immunological response prevails to result in wound unhealing. The functionality of chemo-surveillance dictates the success or the failure of wound healing [13,14]. Wound healing is a simple matter if chemo-surveillance is at a healthy CDA level of 5. Therapy of cancer should also be a simple matter if chemo-surveillance can be restored to the healthy CDA level of 5 [2,15,16].

### **2.3 CDA-2 as An Effective Drug for the Solution of CSCs**

“A perfect cancer drug is a drug capable of destabilizing abnormal MEs to take out both CSCs and CCs by inducing these cells to undergo terminal differentiation, and to restore chemo-surveillance” [44]. Myelodysplastic syndromes (MDS) are a unique case to show the evolution of cancer due to wound unhealing. MDS have been attributed to immunological disorders [45], that prompts the production of inflammatory cytokines. “Among such cytokines, TNF is a critical factor related to the development of MDS, because the antibody of TNF can stop the progression of MDS” [46]. “It causes excessive apoptosis of bone marrow stem cells, thus severely affects the ability of the patient to produce hematopoietic cells such as erythrocytes, platelets or neutrophils. TNF is also responsible for the collapse of chemo-surveillance as above described. As a consequence, chemo-surveillance normally operating in healthy people

to keep PSCs in check becomes dysfunctional, allowing PSCs to build up to evolve into CSCs. The high level of telomerase expression in the peripheral and bone marrow leukocytes in MDS patients is an indication of the widespread multiplication of CSCs" [47,48]. "The propagating pathological cells have been identified as human CSCs" [49]. "So, MDS are ideal for the study of drugs effective against CSCs. So far, Vidaza, Decitabine and CDA-2 are the three drugs approved by the Chinese FDA for the therapy of MDS. Vidaza and Decitabine are also approved by the US FDA for the therapy of MDS. CDA-2 is our creation, which was a preparation of wound healing metabolites purified from freshly collected urine by reverse phase chromatography on XAD-16" [50]. Wound healing metabolites are hydrophobic chemicals that can be retained by C18 and XAD-16. Both peptides and organic acid metabolites are active DIs and DHIs. C18 retains peptides better, but not membrane fragments designated as PP-0, XAD-16 retains acidic metabolites including PP-0 better, but not peptides. So, the very active PP-0 of CDA-2 is only a minor active component of Antineoplastons, and very active acidic peptides of Antineoplastons are not present in CDA-2. Otherwise, CDA-2 and Antineoplastons are similar preparations effective to induce terminal differentiation of both CSCs and CCs. Antineoplastons were blocked by the cancer establishments. CDA-2 was approved by the Chinese FDA, but unlikely it will be accepted by the US FDA. US FDA approved only imperfect cancer drugs that killed CCs.

Inactivation of MEs is the mechanism of action by these three drugs for MDS, CDA-2 by the elimination of telomerase associated with abnormal MEs [50], whereas Vidaza and Decitabine eliminate methyltransferase by covalent bond formation between the enzyme and 5-azacytosine incorporated into DNA [51]. CDA-2 is selective to eliminate the tumor factor of abnormal ME, whereas the covalent bond formation between methyltransferase and 5-azacytosine is non-selective. CDA-2 is devoid of adverse effects, whereas Vidaza and Decitabine are proven carcinogens [52,53] and display considerable toxicity to DNA [54-56]. "Professor Jun Ma, Director of Harbin Institute of Hematology and Oncology, was instrumental to direct clinical trials of all three MDS drugs. According to his assessments based on two cycles of treatment protocols, each cycle 14 days, he has found that CDA-2 had a noticeably better therapeutic efficacy based on cytological

evaluation, and a markedly better therapeutic efficacy based on hematological improvement evaluation, which was an evaluation based on the dependency of blood transfusion to stay healthy" [57]. Obviously, CDA-2 is a better drug for the therapy of MDS, showing superior therapeutic efficacy and devoid of adverse effects. Abnormal MEs are an excellent cancer target, because these enzymes play a pivotal role on the regulation of cell replication and differentiation [58-60]. These enzymes are subjected to exceptional double allosteric regulations: one on the individual enzymes and one on the enzyme complex [61]. Perpetual proliferation is the most outstanding feature of cancer. The blockade of differentiation is a critical factor for cell to keep on replication. Chemo-surveillance is a mechanism created by the nature to prevent the cells with abnormal MEs to build up unnecessarily to become clinical problems. When this mechanism fails, cancer evolves. Chemo-surveillance is the creator's prescription of cancer therapy. The restoration of chemo-surveillance is therefore the top priority of cancer therapy [2]. Chromosomal abnormalities affecting oncogene and suppressor gene expressions are also an important factor on perpetual proliferation of cancer cells. We considered abnormal MEs as the most important factor, namely the bullseye of cancer target [62], because once abnormal MEs are solved, cancer cells will exit cell cycle to undergo terminal differentiation. The abnormal chromosomal problems can also be put to rest. After all, oncogenes and suppressor genes are cell cycle regulatory genes. They have important roles to play when cells are in cell cycle replicating. But if replicating cells exit cell cycle to undergo terminal differentiation, they have no roles to play. Solution of chromosomal abnormalities cannot put away abnormal MEs. Cancer establishments devoted 20 years, 1976-1996, right after the failure to win the war on cancer declared by President Nixon [17], to develop gene therapy [19]. They gave up because it was simply too difficult and too expensive to develop gene therapy. They wasted 20 years to learn the difficulty of gene therapy. They wasted another 20 years, 1996-2016, on the development of anti-angiogenesis [19]. Can they succeed in the development of immunotherapy during 2016-2036? Very unlikely, because the commanding principle of killing CCs is basically wrong! Cancer establishments have killed too many advanced cancer patients [18]. They have to be removed to save advanced cancer patients. [1,26].

CDA-2 is the best drug for the therapy of MDS. Induction of terminal differentiation of CSCs is the only option to cure MDS to generate depleted erythrocytes, platelets or neutrophils. Killing of CSCs cannot cure MDS. Induction of terminal differentiation is definitely the only option to solve CSCs, which are critically linked to wound unhealing. CDA-2 stands out as the best drug on the solution of CSCs. CDA-2 can serve as a good model for the development of effective drugs against CSCs [63].

#### **2.4 Development of CDA Formulations to Target Abnormal MEs for the Elimination of CSCs and CCs**

Cancer is basically a problem of growth regulation going awry. MEs are at the center of growth regulation. Therefore, these enzymes are closely related to cancer. We have presented evidence to indicate that cancer is evolved due to wound unhealing, because of the collapse of chemo-surveillance, thus allowing PSCs to evolve into CSCs, and then to progress to CCs. The solution of CSCs is closely linked to wound unhealing. Therefore, the induction of terminal differentiation of CSCs is the only option to solve the problem of CSCs, just like the completion of wound healing depends on the terminal differentiation of PSCs. The solution of CCs is not as critically linked to wound unhealing as CSCs. CCs can be eliminated by induction of terminal differentiation we prefer or by killing preferred by cancer establishments. The progression of CCs is caused by wound unhealing, wound healing process is the right approach. Therefore, direction of the terminal differentiation of CCs, like the direction of terminal differentiation of CSCs is the right approach. Cancer establishments insist on opposite approach, allowing only killing of CCs by setting up the rule of tumor disappearance as the acceptable cancer drugs. The problem is CSCs refused to be killed, because these cells are protected by drug resistance and anti-apoptosis mechanisms [20-23]. The biological mission of CSCs, like their precursors PSCs, is to repair the wound. Cytotoxic drugs create wounds to trigger the proliferation of CSCs to work on the repair [64]. Eventually, the proportion of CSCs will increase from less than 2% in the primary tumor to reach more than 10% like the primary brain cancers [65,66], which are unresponsive to cytotoxic therapies. Thus, controlling the building up of CSCs is very critical to the success of cancer therapy. Evidently, pro-

wound healing strategy we prefer has the advantage over anti-wound healing strategy preferred by cancer establishments on this issue.

We have carried out extensive studies on natural and unnatural DIs and DHIs for the manufacture of CDA formulations for cancer therapy [5-7,28,31-37,50]. DIs and DHIs can be very effective cancer drugs. ATRA is an effective DI which is the standard care for the therapy of acute promyelocytic leukemia [67]. It requires the expression of the receptor of ATRA, namely RAR, to activate oligoisoadenylate synthetase to achieve the therapeutic effect [68]. The product of this enzyme, oligoisoadenylate, is the actual DI. Gleevec is an effective DHI which is the standard care for the therapy of chronic myeloid leukemia [69]. Thus, effective cancer drugs are not necessary the drugs that must cause the tumor to disappear. ATRA and gleevec cannot cause solid tumor to disappear. So, they are primarily used in the therapy of hematological cancers. The criterion of the therapeutic efficacy of hematological cancers is the disappearance of cancer cells which are morphologically distinguishable from terminally differentiated cells.

“SAHH and MT inhibitors are much better DHIs than MAT inhibitors. MAT is the most stable enzyme of the three MEs” [58]. “The association with telomerase further increases its stability. Therefore, it is not easy to shake loose of this enzyme. Pregnenolone is a major DHI of CDA-2” [5]. “Apparently, pregnenolone is an important player of chemo-surveillance. It is the master substrate of biologically active steroids to exercise a great influence on growth regulation. The production of pregnenolone is bell shape in relation to ages with a peak production of around 50 mg daily at 20-25 years old” [70]. The oldest and youngest people produce relatively little amounts of pregnenolone, and these are the two age groups most vulnerable to develop cancer. It appears that pregnenolone is a single metabolite to greatly influence the evolution of cancer. It is our top choice of natural DHI to make CDA formulations.

“Effective CDA formulations can be  $ED_{25}$  of a DI +  $3xRI_{0.5}$  of a DHI, or  $ED_{50}$  of a DI +  $2xRI_{0.5}$  of a DHI, or  $ED_{75}$  of a DI +  $RI_{0.5}$  of a DHI” [5].  $RI_{0.5}$  of a DHI is equivalent to  $ED_{25}$  of a DI. Reductive index<sub>0.5</sub> ( $RI_{0.5}$ ) can be determined by the procedure provided [64]. These data have been provided in the previous publications above listed. In the design of CDA formulations, we must take

into consideration the non-cancer issues such as blood brain barrier of brain cancer, collagen envelop of pancreatic cancer and hypoxia factor of melanoma to select DIs and DHIs to overcome non-cancer issues, in addition to drug resistance issue of CSCs and degradative enzymes of fast growing CCs we bring up in the previous section 2.2.

### 3. CONCLUSION

A perfect cancer drug must be able to take out both CCs and CSCs, and to restore chemo-surveillance. Induction of terminal differentiation is the only option to solve CSCs. CCs can be taken out by killing or induction of terminal differentiation. CSCs are a dominant issue of metastatic, unresponsive and recurrent cancers, which can be best solved by CDA formulations, or CDA formulations in combination with drugs aimed to kill CCs.

### CONSENT

It is not applicable.

### ETHICAL APPROVAL

It is not applicable.

### ACKNOWLEDGEMENT

We are grateful for the support of the studies on abnormal MEs by Professor Robert B. Hurlbert of University of Texas MD Anderson Hospital and Tumor Institute, and Professor George C. Y. Chiou of Texas A&M University Medical Center, the support of the studies of DIs, DHIs and chemo-surveillance by Dr. Stanislaw R. Burzynski of Burzynski Research Institute, the support of the development of CDA-2 by Mr. Ringo M. L. Chang of Everlife Pharmaceutical Company, and the support of the development of CDA formulations by Professor John P. Fruehauf of Chao' Family Comprehensive Cancer Center of University of California Irvine Medical Center. We appreciate very much the encouragement on the development of CDA formulations by President Joe Biden through personal communications, who has expressed a desire of collaboration to fulfill cancer moonshot initiative he brought up in 2022.

### COMPETING INTERESTS

Authors have declared that no competing interests exist.

### REFERENCES

1. Liau MC, Craig CL, Baker LL. Royal family's cancer diagnoses offer a supreme authority to rectify cancer therapies to save cancer patients. *London J Med Health Res* 2024;24(5):31-43.
2. Liau MC, Craig CL, Baker LL. Restoration of chemo-surveillance as a top priority to save cancer patients. *Intl Res J Oncol*. 2023;6(2):227-237.
3. Liau MC, Craig CL, Baker LL. CDA formulations to fulfill cancer moonshot and to win the war on cancer. *Intl J Res Oncol*. 2023;2(2):1-8.
4. Liau MC, Craig CL, Baker LL. CDA formulations as persuasive good cancer drugs to save cancer patients. *Intl J Clin Oncol Cancer Res*. 2024;9(1):15-24.
5. Liau MC, Fruehauf PA, Zheng ZH, Fruehauf JP. Development of synthetic cell differentiation agent formulations for the prevention and therapy of cancer via targeting of cancer stem cells. *Cancer Stu Ther*. 2019;4(1):1-15.
6. Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes: Nature's way to eradicate cancer stem cells. *J Complement Alt Med*. 2019;2(5):1-5.
7. Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes to combat cancer: Nature's choice to win the war on cancer. *Lambert Academic Publishing*. 2020;978-620-2-66889-7.
8. Dvorak HF. Tumors: Wounds that do not heal. *N Engl J Med*. 1986;315(26):1650-1659.
9. Liau MC, Craig CL, Baker LL. No scar as an indication of perfect wound healing, ugly scar as imperfect wound healing and cancer as failed wound healing. *J Cancer Tumor Intl*. 2022;12(1): 29-34.
10. Liau MC, Craig CL, Baker LL. Wound unhealing as a grave issue of cancer. *Intl Res J Oncol*. 2023;6(1):97-103.
11. Liau MC, Szopa M, Burzynski B, Burzynski SR. Chemo-surveillance: A novel concept of the natural defense mechanism against cancer. *Drugs Exptl Clin Res*. 1987;13(Suppl.1):77-82.
12. Liau MC, Craig CL. On the mechanism of wound healing and the impact of wound on cancer evolution and cancer therapy. *Intl Res J Oncol*. 2021; 5(3):25-31.

13. Liau MC, Baker LL. The functionality of chemo-surveillance dictates the success of wound healing as well as cancer therapy. *Nov Res Sci.* 2021;7(2):1-3.
14. Liau MC, Craig CL. Chemo-surveillance as a natural mechanism to ensure perfection of wound healing to avoid cancer evolution and to cure cancer. In: *New Horizons in Medicine and Medical Research.* 2022;6: 21-28.
15. Liau MC, Craig CL, Baker LL. Wound healing process as the most appropriate modality of cancer therapy. *Eur J Applied Sci.* 2023;11(1):463-471.
16. Liau MC, Craig CL, Baker LL. Wound healing process as the best strategy to save cancer patients. *London J Med Health Res.* 2023;23(13):1-11.
17. Liau MC, Fruehauf JP. It has been half a century since President Nixon declared war on cancer: Destabilization of abnormal methylation enzymes has the blessing of the nature to win the war on cancer. *Adv Complement Alt Med.* 2020;6(1):538-539.
18. Liau MC, Baker LL. Cancer patients' lives matter. *Adv Complement Alt Med.* 2021; 6(5):638-640.
19. Liau MC, Craig CL. Wound healing metabolites to heal cancer and unhealed wounds. *Intl Res J Oncol.* 2022;6(3):8-20.
20. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. *Nat Med.* 2001;7(9): 1028-1034.
21. Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation resistant tumor initiating cells. *Proc Natl Acad Sci USA.* 2010;107(8):3522-3527.
22. Moitra K, Lou H, Dean M. Multidrug efflux pumps and cancer stem cells: Insight into therapy resistance and therapeutic development. *Clin Pharmacol Ther.* 2011; 89(4):491-502.
23. Frame FM, Maitland NJ. Cancer stem cells, model of study and implication of therapy resistance mechanisms. *Adv Exp Med Biol.* 2011;720(2):105-118.
24. Google search on cancer statistics-NCI and American Cancer Society.
25. Liau MC, Fruehauf JP. Winning formulas to fulfill cancer moonshot. *Intl J Res Oncol.* 2022;1(1):1-5.
26. Liau MC, Craig CL, Baker LL. A drastic change of cancer leaderships to save cancer patients. In: *New Advance in Medicine and Medical Science.* 2023;7:61-69.
27. Liau MC, Baker LL. The impact of COVID-19 pandemic on cancer patients. *Intl Res J Oncol.* 2022;6(4):13-17.
28. Liau MC, Lee SS, Burzynski SR. Differentiation inducing components of Antineoplaston A5. *Adv Exptl Clin Chemother.* 1988;6/88:9-26.
29. Burzynski SR. Antineoplastons: History of the research (1). *Drugs Exptl Clin Res.* 1986;12(Suppl. 1):51-56.
30. Liau MC, Szopa M, Burzynski B, Burzynski SR. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of patients undergoing Antineoplaston therapy. *Drugs Exptl Clin Res.* 1987; 13(Suppl. 1):61-70.
31. Liau MC, Kim JH, Fruehauf JP. In pursuance of differentiation inducers to combat cancer via targeting of abnormal methylation enzymes. *J Cancer Tumor Intl.* 2020;10(2):39-47.
32. Liau MC, Kim JH, Fruehauf JP. Arachidonic acid and its metabolites as the surveillance differentiation inducers to protect healthy people from becoming cancer patients. *Clin Pharmacol Toxicol Res.* 2021;4(1): 7-10.
33. Liau MC, Burzynski SR. Separation of active anticancer components of Antineoplaston A2, A3 and A5. *Intl J Tiss React.* 1990;12(Suppl):1-18.
34. Liau MC, Ashraf A, Lee SS, Hendry LB, Burzynski SR. Riboflavin as a minor active anticancer component of Antineoplaston A2 and A5. *Intl J Tiss React.* 1990; 12(Suppl):19-26.
35. Liau MC, Huang L J, Lee JH, Chen SC, Kuo SC. Development of differentiation helper inducers for the differentiation therapy of cancer. *Chin Pharm J.* 1998;50: 289-303.
36. Liau MC, Liau CP. Methyltransferase inhibitors as excellent differentiation helper inducers for differentiation therapy of cancer. *Bull Chin Cancer.* 2002;11:166-168.
37. Liau MC, Kim JH, Fruehauf JP. Potentiation of ATRA activity in HL-60 cells by targeting methyltransferase enzymes. *J Pharmacol Pharmaceu Pharmacovigi.* 2019;3:009. DOI: 10.24969/PPP-5649/100009.
38. MacCarthy-Morrhough L, Martin P. The hallmark of cancer are also the hallmarks



- of wound healing. *Science Signaling*. 2020;13:648.
39. Liau MC, Baker LL. Wound healing, evolution of cancer and war on cancer. *Intl Res J Oncol*. 2021;4(3):13-20.
  40. Ho ATV, Palla AR, Blake MR, Yual ND, Wang YX, Magnusson KEG, et al. Prostaglandin E2 is essential for efficacious skeletal muscle stem function augmenting regeneration and strength. *Proc Natl Acad Sci USA*. 2017;114(26):6675-6684.
  41. Riciotti E, FitzGerald GA. Prostaglandins and inflammation. *Arterioscler Thromb Vasc Biol*. 2011;31(5):986-1000.
  42. Itkin T, Rafii S. Leukemia cells "gas up" leaky bone marrow blood vessels. *Cancer Cell*. 2017; 32(3): 276-278.
  43. Passaro D, Di Tullio A, Abarrategi A, Rousault-Pierre K, Foster K, Ariza-McNaughton L, et al. Increased vascular permeability in the bone marrow microenvironment contribute to disease progression and drug response in acute myeloid leukemia. *Cancer Cell*. 2017;32(3):324-341.
  44. Liau MC. A perfect cancer drug must be able to take out both cancer cells and cancer stem cells, and to restore the functionality of chemo-surveillance. 3<sup>rd</sup> International Conference on Medicinal Chemistry and Drug Design. 2021:13.
  45. Williamson PJ, Druger AR, Reynolds PJ, Hamlin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndromes. *Br J Haemato*. 1994;87(4):743-745.
  46. Boula A, Vougarelis M, Giannouli S, Katrinakis G, Psyllaki M, Pontikoglou C, et al. Effect of CA2 of antitumor necrosis factor-alpha antibody therapy on hematopoiesis of patient with myelodysplastic syndromes. *Clin Cancer Res*. 2006;12(10):3099-3108.
  47. Counter CM, Gupta J, Harley CB, Lever B. Telomerase activity in normal leukocytes and hematological malignancies. *Blood*. 1995;85(9):2315-2320.
  48. Fu C, Chen Z. Telomerase activities in myelodysplastic syndromes. *Chin Med J (Engl)* 2002;115(10):1475-1478.
  49. Woll PS, Kjallquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells *In vivo*. *Cancer Cell*. 2014;25(6):794-808.
  50. Liau MC. Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof. US Patent. 2007;7232578 B2.
  51. Santi DV, Norment A, Garret CE. Covalent bond formation between a DNA-cytosine methyltransferase of DNA containing 5-azacytosine. *Proc Natl Acad Sci USA*. 1984;81(22):6993-6997.
  52. Prassana P, Shack S, Wilson VL, Samid D. Phenylacetate in chemoprevention of 5-aza-2'-deoxycytidine-induced carcinogenesis. *Clin Cancer Res*. 1995; 1(18):865-871.
  53. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, et al. Induction of tumor in mice by genomic hypomethylation. *Science*. 2003; 300(5618): 489-492.
  54. Pali SS, van Emburgh BO, Sankpal UJ, Brown KD, Robertson KD. DNA methylation inhibitor 5-aza-2'-deoxycytidine induces reversible DNA damage that is distinctly influenced by DNA methyltransferase 1 and 3B. *Mol Cell Biol*. 2008; 28(2): 752-771.
  55. Kizietepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, et al. 5-Azacytidine, a methyltransferase inhibitor, induces ATR-mediated DNA-double strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicine and bortezomib against multiple myeloma cells. *Mol Cancer Ther*. 2007;6(6):1718-1727.
  56. Yang Q, Wu F, Wang F, Cai K, Zhang Y, Sun Q, et al. Impact of DNA methyltransferase inhibitor 5-azacytidine on cardiac development of zebrafish in vivo and cardiomyocyte proliferation, apoptosis, and the homeostasis of gene expression in vitro. *J Cell Biochem*. 2019;120(10): 17459-17471.
  57. Ma J. Differentiation therapy of malignant tumor and leukemia. *CISCO Treaties on the Education of Clinical Oncology*. 2007:480-486.
  58. Liau MC, Chang CF, Saunder GF, Tsai YH. S-Adenosylhomocysteine hydrolases as the primary target enzymes in androgen regulation of methylation complexes. *Arch Biochem Biophys*. 1981;208(1):261-272.
  59. Liau MC. Abnormal methylation enzymes: A selective molecular target for differentiation therapy of cancer. *Chin Pharm J*. 2004 56(2): 57-67.
  60. Liau MC, Craig CL, Baker LL. Abnormal methylation enzymes as the most critical

- issue of cancer. Intl Res J Oncol. 2023; 6(2):168-176.
61. Liau MC, Craig CL, Baker LL. Exceptional allosteric regulation of methylation enzymes. In: Novel Research Aspects in Medicine and Medical Research. 2023; 4:39-56.
62. Liau MC, Baker LL. Abnormal methylation enzymes as the bullseye of targeted cancer therapy. Nov Res Sci. 2021;7(4):1-3.
63. Liau MC, Craig CL, Baker LL. Development of good cancer drugs effective against cancer stem cells. Intl Res J Oncol. 2023;6(2):238-247.
64. Liau MC, Baker LL. Destruction promotes the proliferation of progenitor stem cells and cancer stem cells. Therefore, non-destruction strategy is a better choice for cancer therapy. J Pharmacol Pharmaceu Pharmacovigi. 2020;4:029. DOI: 10.24966/PPP-5649/100029.
65. Mongeri-Sacca M, Dimrino S, Der Maria R. Biological and clinical implication of cancer stem cells in primary brain tumors. Front Oncol. 2013;3:6.
66. Liu YC, Lee IC, Chen PY. Biomimetic brain tumor niche regulates glioblastoma cells toward a cancer stem cell phenotype. J Neurooncol. 2018;139(3) 511-522.
67. Huang M, Ye Y, Chen S, Wang ZY. Use of all trans-retinoic acid for the treatment of promyelocytic leukemia. Blood. 1988;97: 567-572.
68. Bourgead MF, Beasoncon F. Induction of 2', 5'-oligoadenylate synthetase by retinoic acid in two transformed human cell lines. Cancer Res. 1984;44:5355-5360.
69. Le Coutre P, Mologui L, Cleris L, Marchesi E, Euchdunger E, Giardini R, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst. 1999;91:163-168.
70. Morley JE. Hormone, aging and endocrines in the elderly. In: Felig P. Frohman LA: Endocrinology and Metabolism, 4<sup>th</sup> ed, McGraw Hill Inc, Medical Publishing Division, New York. 2001;1455-1482.

---

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:*  
<https://www.sdiarticle5.com/review-history/117442>